Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
525 participants
OBSERVATIONAL
2017-03-01
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epidemiology of SAIDs.
NCT03643809
Validation of a Prognostic Score for Steroid Therapy Response in Acute Severe Autoimmune Hepatitis
NCT05473403
Inflammatory Marker in Ibd and Peripheral Arthritis
NCT05705232
Frequency and Risk Factors for Autoimmune Disorders and Rheumatic Manifestations in Egyptian Patients With IBD
NCT05771363
Search for BIO Diagnostic and Prognostic Markers in Adult VAScularitis
NCT05565885
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least one urine sample
Exclusion Criteria
* Persons under protection
* Paritcipation rejections
* Admition to the ICU after scheduled surgery or trauma or suicide attempt unrelated to neurological involvement of SRD
* Cancer treated with chemotherapy within a month before ICU admission
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Groupe Hospitalier Pitie-Salpetriere
OTHER
Sorbonne University
OTHER
Hôpital Lariboisière Fernand Widal
OTHER
Université Montpellier
OTHER
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Romaric Larcher, MD PhD
Role: STUDY_DIRECTOR
UH Montpellier
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uhmontpellier
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECHMPL18_0289
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.